-
-
-
-
-
-
-
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
-
-
-
-
-
-
-
Chardan Capital Markets Downgrades Seres Therapeutics (MCRB) to Neutral
-
-
-
-
-
-
-
Seres Therapeutics (MCRB) Misses Q3 EPS by 25c
-
-
-
-
-
-
-
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
-
-
-
-
-
-
-
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
-
1,216,193 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

